Advertisement|Remove ads.

Shares of Classover Holdings Inc. (KIDZ) gave up some of its pre-market gains to trade 12% on Friday, after the company announced a memorandum of understanding with robotics education company Walimaker to bring robotics and AI learning programs to the North American K-12 market, covering kindergarten through 12th grade.
The partnership will leverage Classover’s digital education platform, learning centers, and summer camp channels and Walimaker’s robotics programming curriculum and hands-on engineering systems, Classover said.
Walimaker’s robotics ecosystem includes robotics kits, coding curriculum, and interactive learning modules designed to build engineering and problem-solving skills. The company added that its programs are used in more than 600 learning centers and schools.
Earlier this month, Classover terminated a $400 million equity purchase facility with Solana Strategic Holdings, ending its Solana-focused digital asset treasury strategy. The company said it would redirect investment toward artificial intelligence and robotics to support long-term growth and reduce potential share dilution.
Shortly after exiting the digital-asset strategy, the company announced a strategic collaboration with YuGuang AI, an education technology firm focused on AI-generated instructional content. The partnership is set to explore developing AI-driven curriculum solutions, including tools for content creation, instructional design, and video-based learning.
Separately, Classover also implemented a 1-for-50 reverse stock split of its Class A and Class B common shares on March 9. Following the split, outstanding Class A shares decreased to about 130,700 from over 6.5 million, while Class B shares fell to roughly 1.1 million from nearly 55 million.
Retail sentiment on Stocktwits for KIDZ remained in the ‘bullish’ territory over the past 24 hours, amid ‘high’ message volumes.
One user sees resistance at $3.3. It is currently trading around $3.
Read also: IBRX Stock Rises 3% Pre-Market: ImmunityBio Reports Breakthrough In NK Cell Therapy Production
For updates and corrections, email newsroom[at]stocktwits[dot]com.